Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVESICALStandard

ANKTIVA

nogapendekin alfa inbakicept-pmln

Standard Dose
400mcg/0.4 mL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ANKTIVA is listed in Drugs@FDA under application 761336 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient nogapendekin alfa inbakicept-pmln Form and strength SOLUTION;INTRAVESICAL - 400mcg/0.4 mL Sponsor ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU Submission history Latest submission status date: 2024-04-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview ANKTIVA is listed in Drugs@FDA under application 761336 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient nogapendekin alfa inbakicept-pmln Form and strength SOLUTION;INTRAVESICAL - 400mcg/0.4 mL Sponsor ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU Submission history Latest submission status date: 2024-04-22 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.